AtriCure, Inc. Stock

$30.72

4.18% day before yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US04963C2098

Symbol

ATRC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

AtriCure, Inc. Stock price

$30.72

-12.25 28.51% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-1.34 4.18%

ISIN

US04963C2098

Symbol

ATRC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$1.5b

Enterprise Value

$1.5b

Net debt

positive

Cash

$99.9m

Shares outstanding

49.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

3.2 | 2.9

EV/Sales

3.1 | 2.8

EV/FCF

negative

P/B

3.4

Financial Health

Equity Ratio

75.7%

Return on Equity

-9.7%

ROCE

-6.6%

ROIC

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

$480.1m | $533.4m

EBITDA

$-32.0m | $45.5m

EBIT

$-35.1m | $-25.1m

Net Income

$-38.2m | $-26.8m

Free Cash Flow

$-670.0k

Growth (TTM | estimate)

Revenue

15.8% | 14.6%

EBITDA

-10.7% | 223.1%

EBIT

-10.3% | 37.3%

Net Income

-2.5% | 40.1%

Free Cash Flow

98.8%

EPS

$-0.8

FCF per Share

$0.0

Short interest

3.3%

Employees

Rev per Employee

$360.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

AtriCure, Inc. Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a AtriCure, Inc. forecast:

14x Buy

93%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a AtriCure, Inc. forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from AtriCure, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	480 480	16% 16% 100%
- Direct Costs	121 121	18% 18% 25%
Gross Profit	359 359	15% 15% 75%
- Selling and Administrative Expenses	294 294	12% 12% 61%
- Research and Development Expense	97 97	23% 23% 20%
EBITDA	-32 -32	11% 11% -7%
- Depreciation and Amortization	3.04 3.04	6% 6% 1%
EBIT (Operating Income) EBIT	-35 -35	10% 10% -7%
Net Profit	-38 -38	2% 2% -8%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

AtriCure, Inc. Stock News

Neutral

Business Wire

●

5 days ago

AtriCure to Announce Second Quarter 2025 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2025 financial results on Tuesday, July 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on ...

Neutral

Business Wire

●

about 2 months ago

AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a...

Neutral

Seeking Alpha

●

2 months ago

AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript

AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial C...

More AtriCure, Inc. News

Company Profile

AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.

Head office	United States
CEO	Michael Carrel
Employees	1,300
Founded	1994
Website	www.atricure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now